LY2090314
目录号: PL04605 纯度: ≥99%
CAS No. :603288-22-8
商品编号 规格 价格 会员价 是否有货 数量
PL04605-5mg 5mg ¥1038.00 请登录
PL04605-10mg 10mg ¥1661.00 请登录
PL04605-25mg 25mg ¥2995.00 请登录
PL04605-50mg 50mg ¥4550.00 请登录
PL04605-100mg 100mg ¥7930.00 请登录
PL04605-200mg 200mg 询价 询价
PL04605-500mg 500mg 询价 询价
PL04605-10mM*1mLinDMSO 10mM*1mLinDMSO ¥1401.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
LY2090314
中文别名
LY2090314 抑制剂
英文名称
LY2090314
英文别名
LY2090314;Kinome_3681;LY-2090314;3-[9-Fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-1h-pyrrole-2,5-dione;3-[9-Fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indol-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-1H-pyrrole-2,5-dione;7-(2,5-Dihydro-4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-1H-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepine;LY 2090314;822M3GYM67;3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione;GTPL7958;HMS3747E07;BCP07855;s7063;BDBM50150699;Kinome_3681, LY2090314;DB11913;SB16558;BC600682;AK547885;3-[6-Fluoro-10-(piperidine-1-carbonyl)-1,10-diazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-3-
Cas No.
603288-22-8
分子式
C28H25FN6O3
分子量
512.53
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
LY2090314 是一种有效的 GSK-3 抑制剂,抑制 GSK-3α 和 GSK-3β,IC50 值分别为 1.5 nM 和 0.9 nM。
生物活性
LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC 50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
性状
Solid
IC50 & Target[1][2]
GSK-3β 0.9 nM (IC50) GSK-3α 1.5 nM (IC
体外研究(In Vitro)
LY2090314 (20 nM) promotes a time-dependent stabilization of β-catenin total protein as well as an induction of Axin2. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of kinases. LY2090314 potently induces apoptotic cell death in a panel of melanoma cell lines irrespective of BRAF mutation status. Cell death induced by LY2090314 is dependent on β-catenin and GSK3β knockdown increases the sensitivity of cells to LY2090314. LY2090314 remains active in cell lines resistant to PLX4032 and has an independent mechanism of action. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
LY2090314 exhibits high clearance (approximating hepatic blood flow) and a moderate volume of distribution (appr 1-2 L/kg) resulting in rapid elimination (half-life appr 0.4, 0.7, and 1.8-3.4 hours in rats, dogs, and humans, respectively). LY2090314 is rapidly cleared by extensive metabolism with negligible circulating metabolite exposures due to biliary excretion of metabolites into feces with no apparent intestinal reabsorption. LY2090314 (25 mg/kg Q3D, i.v.) elevates Axin2 gene expression in vivo, demonstrates single agent activity in the A375 xenograft model of melanoma and enhances the efficacy of DTIC. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Zamek-Gliszczynski MJ, et al. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Dr
[2]. Atkinson JM, et al. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One. 2015 Apr 27;10(4):e0125028.
溶解度数据
In Vitro: DMSO : 25 mg/mL (48.78 mM; ultrasonic and warming and heat to 60°C)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2